Notes 6-10

10 INTANGIBLE ASSETS

	Product, marketing and distribution rights $m	Other intangibles $m	Software development costs $m	Total $m
Cost
At 1 January 2005	3,202	477	596	4,275
Additions – separately acquired	43	57	76	176
Exchange adjustments	(442)	(31)	(23)	(496)
At 31 December 2005	2,803	503	649	3,955
Additions – through business combinations	1,260	281	–	1,541
Additions – separately acquired	413	51	121	585
Disposals	(675)	(4)	–	(679)
Exchange adjustments	372	79	16	467
At 31 December 2006	4,173	910	786	5,869
Additions – through business combinations	6,946	1,477	–	8,423
Additions – separately acquired	299	33	178	510
Disposals	(52)	(82)	–	(134)
Exchange adjustments	183	47	12	242
At 31 December 2007	11,549	2,385	976	14,910
Amortisation and impairment losses
At 1 January 2005	1,507	335	372	2,214
Amortisation for year	214	19	39	272
Exchange adjustments	(288)	3	(5)	(290)
At 31 December 2005	1,433	357	406	2,196
Amortisation for year	250	25	50	325
Disposals	(14)	(4)	–	(18)
Impairment	–	17	–	17
Exchange adjustments	190	48	4	242
At 31 December 2006	1,859	443	460	2,762
Amortisation for year	364	112	78	554
Disposals	(52)	(81)	–	(133)
Impairment	98	22	–	120
Exchange adjustments	104	32	4	140
At 31 December 2007	2,373	528	542	3,443
Net book value
At 31 December 2005	1,370	146	243	1,759
At 31 December 2006	2,314	467	326	3,107
At 31 December 2007	9,176	1,857	434	11,467

Amortisation charges are recorded in selling, general and administrative costs and research and development costs in the income statement.

The impairment in 2007 was in relation to the termination of a product in development acquired with MedImmune and four collaboration agreements.

The impairment in 2006 was in relation to the termination of NXY-059 and a collaboration agreement.

These costs were included in research and development in the income statement in both years.

	Description	Carrying value $m	Remaining amortisation period
Intangible assets arising from joint venture with Merck¹	Product, marketing and distribution rights	298	6 and 10 years
Advance payment¹	Product, marketing and distribution rights	704	11 years
Intangible assets arising from the acquisition of CAT	Product, marketing and distribution rights	585	8 and 13 years²
Intangible assets arising from the acquisition of KuDOS	Product, marketing and distribution rights	285	Not amortised²
Intangible assets arising from the acquisition of MedImmune	Product, marketing and distribution rights	5,916	18-24 years
Intangible assets arising from the acquisition of MedImmune	Licencing and contractual income	1,314	2-13 years
Intangible assets arising from the acquisition of MedImmune	Product, marketing and distribution rights	576	Not amortised²

¹These assets are associated with the restructuring of the joint venture with Merck & Co., Inc. Further information can be found in Note 27.

²Assets in development are not amortised but are tested annually for impairment.